Pathogenic <i>LRRK2</i> variants are gain-of function mutations that enhance LRRK2-mediated repression of β-catenin signaling by Berwick, Daniel C. et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Pathogenic LRRK2 variants are gain-of function
mutations that enhance LRRK2-mediated repression of
-catenin signaling
Journal Item
How to cite:
Berwick, Daniel C.; Javaheri, Behzad; Wetzel, Andrea; Hopkinson, Mark; Nixon-Abell, Jonathon; Granno,
Simone; Pitsillides, Andrew A. and Harvey, Kirsten (2017). Pathogenic LRRK2 variants are gain-of function mutations
that enhance LRRK2-mediated repression of -catenin signaling. Molecular Neurodegeneration, 12, article no. 9.
For guidance on citations see FAQs.
c© 2017 The Authors
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1186/s13024-017-0153-4
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
RESEARCH ARTICLE Open Access
Pathogenic LRRK2 variants are gain-of-
function mutations that enhance LRRK2-
mediated repression of β-catenin signaling
Daniel C. Berwick1,2, Behzad Javaheri3, Andrea Wetzel1, Mark Hopkinson3, Jonathon Nixon-Abell1, Simone Grannò1,
Andrew A. Pitsillides3 and Kirsten Harvey1*
Abstract
Background: LRRK2 mutations and risk variants increase susceptibility to inherited and idiopathic Parkinson’s disease,
while recent studies have identified potential protective variants. This, and the fact that LRRK2 mutation carriers
develop symptoms and brain pathology almost indistinguishable from idiopathic Parkinson’s disease, has led to
enormous interest in this protein. LRRK2 has been implicated in a range of cellular events, but key among them is
canonical Wnt signalling, which results in increased levels of transcriptionally active β-catenin. This pathway is critical
for the development and survival of the midbrain dopaminergic neurones typically lost in Parkinson’s disease.
Methods: Here we use Lrrk2 knockout mice and fibroblasts to investigate the effect of loss of Lrrk2 on canonical Wnt
signalling in vitro and in vivo. Micro-computed tomography was used to study predicted tibial strength, while
pulldown assays were employed to measure brain β-catenin levels. A combination of luciferase assays,
immunofluorescence and co-immunoprecipitation were performed to measure canonical Wnt activity and investigate
the relationship between LRRK2 and β-catenin. TOPflash assays are also used to study the effects of LRRK2 kinase
inhibition and pathogenic and protective LRRK2 mutations on Wnt signalling. Data were tested by Analysis of Variance.
Results: Loss of Lrrk2 causes a dose-dependent increase in the levels of transcriptionally active β-catenin in the brain,
and alters tibial bone architecture, decreasing the predicted risk of fracture. Lrrk2 knockout cells display increased
TOPflash and Axin2 promoter activities, both basally and following Wnt activation. Consistently, over-expressed LRRK2
was found to bind β-catenin and repress TOPflash activation. Some pathogenic LRRK2 mutations and risk variants
further suppressed TOPflash, whereas the protective R1398H variant increased Wnt signalling activity. LRRK2 kinase
inhibitors affected canonical Wnt signalling differently due to off-targeting; however, specific LRRK2 inhibition reduced
canonical Wnt signalling similarly to pathogenic mutations.
Conclusions: Loss of LRRK2 causes increased canonical Wnt activity in vitro and in vivo. In agreement, over-expressed
LRRK2 binds and represses β-catenin, suggesting LRRK2 may act as part of the β-catenin destruction complex. Since
some pathogenic LRRK2 mutations enhance this effect while the protective R1398H variant relieves it, our data
strengthen the notion that decreased canonical Wnt activity is central to Parkinson’s disease pathogenesis.
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Background
Parkinson’s disease (PD) is an incurable progressive
movement disorder that is characterized by the degener-
ation of dopaminergic neurons of the substantia nigra
pars compacta. PD is the second most common neuro-
degenerative disease worldwide [1–3]. Although typically
idiopathic, genetic studies have identified a strong
hereditary contribution to PD risk. Interest in PD-causing
mutations in the LRRK2 gene is particularly strong, since
LRRK2 mutations account for up to 40% of PD cases in
some populations, and elicit symptoms and brain patholo-
gies resembling idiopathic PD [1–3]. As such, uncovering
the function of LRRK2 is expected to be hugely inform-
ative for understanding early PD aetiology and developing
novel treatments for this condition.
LRRK2 encodes leucine-rich repeat kinase 2 (LRRK2),
a 2527 amino acid protein that has been implicated in
the regulation of various cellular functions, including au-
tophagy and endocytosis. LRRK2 contains two distinct
enzymatic activities, namely serine/threonine kinase
activity and GTPase activity, the latter conferred by a
RocCOR (Ras of complex proteins; C-terminal of Roc)
tandem domain. The combination of these enzymatic
activities suggests a function for LRRK2 in signal trans-
duction [1, 2, 4–6]. LRRK2 has been implicated in the
regulation of a number of signal transduction pathways,
for example JNK [7], FAS [8], NFAT [9], and NF-κB
[10]. In addition, LRRK2 has been reported to be phos-
phorylated by IκK kinases in response to Toll-like recep-
tor activation [11], and by casein kinase 1α [12].
However, a definitive, conserved cellular role for LRRK2
has yet to emerge, suggesting that it may serve distinct
functions in different cell types [6].
Another signal transduction cascade linked to LRRK2
is canonical Wnt signalling [13–19]. Wnt (Wingless/Int)
pathways are a family of evolutionarily conserved signal
transduction cascades best described in developmental
biology and cancer [20–22]. Activation of the canonical
Wnt pathway, induces the nuclear accumulation of the
transcriptional co-factor β-catenin, with resultant
changes in gene expression [20–22]. In the absence of
stimulus, β-catenin is repressed by retention in a multi-
protein β-catenin destruction complex. Here, β-catenin
is phosphorylated by glycogen synthase kinase-3β
(GSK3β) triggering its continual ubiquitination and deg-
radation [20–22].
Perturbed canonical Wnt signalling has been
suggested to underlie a variety of clinical conditions. In-
creased Wnt activity is well established in the causation
of many types of cancer, most notably cancers of the
bowel [21], whilst decreased Wnt signalling is heavily
involved in melanoma [23]. Alterations in Wnt signalling
are also implicated in kidney disease [24], pulmonary
and hepatic fibroses [25, 26], and a number of
neurological conditions, including Alzheimer’s disease,
Schizophrenia, depression, and Parkinson’s disease
[27–29]. The above list notwithstanding, the bodily tissue
that appears most exquisitely sensitive to changes in Wnt
signalling is bone. In both humans and mice, increased
Wnt signalling has been shown to cause increased bone
strength and, in severe cases, osteopetrosis [30–35]. Con-
versely, decreased Wnt signalling leads to weakened bones
and osteoporosis [30, 36–41].
We previously reported a role for LRRK2 as a scaffold
protein in canonical Wnt signalling [16]. Via direct
interaction with the co-receptor LRP6 [16], dishevelled
(DVL) proteins [14] and GSK3β [15], LRRK2 assists in
the formation of signalosomes following activation of
the canonical Wnt pathway. Interestingly, the strength
of interactions between LRRK2 and LRP6, DVLs and
GSK3β are all affected by LRRK2 mutations [14–16] and
consistent with this, the extent to which over-expressed
LRRK2 is able to augment DVL1-driven canonical Wnt
activation was reduced by the pathogenic R1441C,
Y1699C and G2019S LRRK2 mutations [16]. The LRRK2
PD risk variant, G2385R, behaves similarly in these as-
says [18]. Most notably, the protective LRRK2 variant,
R1398H, has the opposite effect, actually enhancing
DVL1-driven β-catenin activation [18]. Curiously how-
ever, despite our data supporting a positive role for
LRRK2 in activated Wnt signalling, siRNA-mediated
knockdown of this protein also led to enhanced Wnt ac-
tivation, both under basal and stimulated conditions
[16]. We hypothesized that this represented an
additional role for LRRK2 in basal Wnt signalling, as a
component of the β-catenin destruction complex.
Here, we provide compelling evidence that the primary
role of LRRK2 in the canonical Wnt pathway is as a re-
pressor of β-catenin. Fibroblasts derived from LRRK2
knockout mice display enhanced canonical Wnt activity
compared to wild-type controls, whilst over-expressed
LRRK2 inhibits transcription driven by exogenous β-
catenin. Most importantly, aged LRRK2 knockout mice
display increased predicted tibial bone strength as well
as increased free β-catenin levels in brain. Finally, we
present evidence that LRRK2 mutations are inhibitory to
canonical Wnt signalling under tonic conditions, while
the protective R1398H variant enhances this pathway.
Thus, our data strengthen the growing connection be-
tween LRRK2, PD and the canonical Wnt pathway.
Methods
Mice
B6.129X1(FVB)-Lrrk2tm1.1Cai/J (“Lrrk2 knockout”) animals,
containing a targeted deletion of exon 2 of the Lrrk2 gene
[42], were obtained from Jackson Labs and housed at the
UCL School of Pharmacy. Lrrk2 knockout mice were bred
against a C57BL/6J background and genotyped according to
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recommended protocols. All procedures followed UK Home
Office approval.
High-resolution micro-computed tomography (μ-CT)
Tibiae from 60 to 64 week old (n = 7/age group) Lrrk2
knockout and wild-type female mice were fixed in 4%
paraformaldehyde and stored in 70% EtOH until scan-
ning using the Skyscan 1172 (Skyscan, Kontich,
Belgium), with the x-ray tube operated at 50 kV and
200 μA, 1600 ms exposure time with a 0.5 mm alumin-
ium filter and a voxel size of 5 μm. The scanning time
for each sample was approximately 2 h. The slices were
then reconstructed using NRecon 1.6.9.4 (Skyscan, Kon-
tich, Belgium). 2D/3D analyses were performed using
CTAn 1.13.5.1+ version software (Skyscan, Kontich,
Belgium). Finally, CTvox 2.7.0 r990 version (Skyscan,
Kontich, Belgium) was used for 3D visualization [43].
Morphometrical analysis
Trabecular analysis
Prior to analysis, μ-CT images were re-oriented in Data-
Viewer 1.5.0 (Skyscan, Kontich, Belgium), such that the
cross-section within the transverse plane was perpen-
dicular to the long axis of the bone. Tibial length was
measured in CTAn 1.13.5.1+ software using a straight
line measuring tool and the appearance of the trabecular
‘bridge’ connecting the two primary spongiosa bone
‘islands’ was set as reference point for analysis of the
metaphyseal trabecular bone adjacent to the epiphyseal
growth plate. 5% of the total bone length from this point
(towards the diaphysis) was utilised for trabecular
analysis of the proximal tibia. The selected trabecular re-
gions of interests were analysed using CTAn BatMan
software (Skyscan, Kontich, Belgium) and morphometric
parameters were recorded.
Whole bone cortical analysis
Whole bone analysis was performed on datasets derived
from whole CT scans using BoneJ (version 1.13.14) [44]
a plugin for ImageJ [45]. Following segmentation, align-
ment and removal of fibula from the dataset, a minimum
bone threshold was selected for each bone to separate
higher density bone from soft tissues and air. The most
proximal and the most distal 10% portions of tibial
length were excluded from analysis, as these regions
include trabecular bone. This threshold was used in
“Slice Geometry” within BoneJ to calculate cross sec-
tional area (CSA), second moment of area around the
minor axis (Imin), second moment of area around the
major axis (Imax), mean thickness determined by local
thickness in two dimensions (Ct.Th), Ellipticity, resist-
ance to torsion (J) and section modulus around the
major (Zmax) and minor (Zmin) axes.
Mouse brain biochemistry
Preparation of protein extracts
Brains taken from 22 to 26 week old male or 60–64
week old female mice were rinsed in phosphate-buffered
saline (PBS) and immediately transferred to ice. All
subsequent steps were performed at 4 °C. Brains were
homogenized into 5 ml brain lysis buffer [50 mM Tris,
pH 7.5, 150 mM NaCl, 5 mM MgCl2 and 1% (v/v) NP-
40, supplemented with 1× complete protease inhibitor
cocktail (Roche) and 1× Halt phosphatase inhibitor
cocktail (Pierce)] using a dounce homogenizer and then
clarified by centrifugation at 14 000 g for 10 min. Samples
for Western blotting were denatured by the addition of 4×
LDS sample loading buffer and 10× sample reducing agent
(both Invitrogen) followed by heating to 99 °C for 10 min.
Samples for ECT pulldown experiments were assayed for
protein concentration by bicinchoninic acid (BCA) assay
(Pierce).
ECT pulldowns of Free β-Catenin
Active β-catenin was pulled-down from lysates using a
protocol derived from that described by Luckert and col-
leagues [46]. Briefly, brains were extracted as above and
a volume equivalent to 2 mg total protein taken from
each lysate and added to 20 μl GST-ECT beads. Pull-
downs were performed by incubating beads and lysates
overnight at 4 °C on a rotor, to allow the binding of
monomeric β-catenin to ECT protein. The next morn-
ing, GST-ECT beads were washed five times in brain
lysis buffer before protein complexes were denatured by
the addition of 4× LDS sample loading buffer and 10×
sample reducing agent (both Invitrogen) followed by
heating to 99 °C for 10 min.
Generation of GST-ECT beads
To induce expression of GST-ECT protein, BL21
Escherichia coli cells transformed with pETM33-ECT
were grown to an OD600 of 0.5 and treated with
100 μM (final concentration) Isopropyl β-D-1-thio-
galactopyranoside (IPTG), prior to culture at 30 °C
for 5 h. Cells were pelleted by centrifugation and pel-
lets washed twice with ice-cold PBS. Bacterial pellets
were resuspended in 25 ml of bacterial lysis buffer
[20 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl2,
2 mM EDTA (pH 8), 1% (v/v) Triton X-100, 1X
complete protease inhibitor cocktail (Roche), 2 mM
dithiothreitol, 0.25 mg/ml lysozyme (Sigma) and
10 μg/ml DNAseI (Sigma)] and subjected to at least
three freeze-thaw cycles. Extracts were clarified by
centrifugation and transferred to a fresh tube, with a
small aliquot used to verify protein expression by
Coomassie staining. In parallel, 1 ml of Glutathione
Sepharose 4 Fast Flow beads (GE Healthcare) was
washed in 5 ml bacterial lysis buffer. To generate
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GST-ECT beads, the beads were added to cleared
bacterial lysate and incubated for 30 min at 4 °C on a
rotator. Beads were washed five times in bacterial
lysis buffer and resuspended in the same buffer sup-
plemented with 50% glycerol, prior to storage at
−20 °C. GST-ECT beads were equilibrated into brain
lysis buffer before use in ECT pulldown experiments.
Expression constructs
pcDNA3-FLAG-β-catenin (Addgene plasmid #16828;
[47]), Axin2-luciferase (Addgene plasmid #21275; [48]),
V405 HA-CK1ε (wild-type) and V406 HA-CK1ε (K38R)
(Addgene plasmids #13724 and #13725; [49]), and HA
GSK3 beta wt pcDNA3 (Addgene plasmid #14753; [50])
were gifts from Eric Fearon, Frank Costantini, David
Virshup, and Jim Woodgett respectively. pCMV5-HA-
AXIN1 was obtained from MRC PPU Reagents.
Mammalian expression plasmids encoding myc-tagged
LRRK2 with N1437H and R1628P mutations were made
using site-directed mutagenesis to pRK5-mycLRRK2
[14]. Plasmids were verified by DNA sequencing.
pETM33-ECT was made by PCR amplification of DNA
encoding amino acids 732 to the end of E-cadherin
protein from human brain cDNA, follow by in-frame
insertion into the NcoI and SalI site of the bacterial
expression plasmid, pETM-33. Primers: forward:
ctgtccatggggaggagagcggtggtcaaagag; reverse: ctcgcagctgc-
tagtggtcctcgccgcctccg. All other constructs have been
described previously [14, 16, 18, 51].
Cell culture and Transfection
HEK293 cells (ATCC CRL1573) and LRRK2 knockout
and wild-type control mouse embryonic fibroblast cells
[51] were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) foetal bovine
serum, 2 mM glutamine, 100 U/ml penicillin G and
100 μg/ml streptomycin at 37 °C in 95% air-5% CO2.
Cells for immunofluorescence were seeded onto poly-d-
lysine-coated coverslips. In all cases cells were trans-
fected with Fugene HD reagent (Roche) and harvested
24 h post-transfection.
Inhibitor treatments
The LRRK2 kinase inhibitors LRRK2-in-1 [52],
TAE684 [53] and CZC25146 [54] were kindly
provided by the Michael J. Fox Foundation. All com-
pounds were resuspended in DMSO, with serial dilu-
tions also made using DMSO. Cells were transferred
into media containing inhibitors at the indicated con-
centrations (or DMSO only) 6 h after transfection
and incubated for 20 h prior to lysis. The final
DMSO concentration was fixed at 0.1% (v/v).
Co-Immunoprecipitation
Cells were grown in 10 cm plates and transfected with
4 μg of the relevant plasmids. Twenty-four hours later
cells were lysed in a solution containing 150 mM NaCl,
50 mM Tris (pH 7.5), 2 mM EDTA (pH 8), 1% (v/v)
Triton X-100, plus 1X complete protease inhibitor cock-
tail (Roche) and 1X Halt phosphatase inhibitor cocktail.
Following centrifugation (4 °C, 15 min, 16,000 g) 1 ml of
cell lysate was added to 40 μl of anti-FLAG M2 affinity
gel (Sigma) and incubated for 1 h at 4 °C on a turning
disk. The affinity gel was washed four times in extraction
buffer and FLAG fusion proteins eluted with 150 ng of
3 × FLAG peptide (Sigma) for 30 min at room
temperature. Eluates were denatured by the addition of
4× LDS sample loading buffer and 10× sample reducing
agent (both Invitrogen) followed by heating to 99 °C for
10 min.
Western blotting
Protein samples were loaded onto 4–12% (w/v) BisTris
pre-cast gels (Invitrogen). Proteins were transferred to
polyvinylidine fluoride (PVDF) membranes (Millipore),
rinsed briefly in Tris-buffered saline plus 0.1% (v/v)
Tween 20 (TBS-T), and blocked by incubation in TBS-T
containing 5% (w/v) non-fat dry milk (blocking buffer)
for 30 min. Primary antibody incubations were
performed in blocking buffer overnight at 4 °C. Antibody
concentrations used were: Anti-myc (Sigma), 1:2000 di-
lution; anti-FLAG (Sigma), 1:2000 dilution; anti-β-
catenin (Cell Signaling Technologies), 1:2000; anti-
Calnexin (AbCam), 1:3000 dilution; rabbit anti-LRRK2
(Epitomics ‘MJFF2’), 1:1000; and mouse anti-LRRK2
(NeuroMab ‘N138/6’), 1:1000. The following morning,
membranes were washed three times in TBS-T, prior to
incubation in HRP-conjugated secondary antibody
(Santa Cruz) at 1:2000 in blocking buffer for 1 h at room
temperature. After an additional three washes, staining
was visualized using SuperSignal West Pico Chemilu-
minescent Substrate or SuperSignal West Femto Chemi-
luminescent Substrate (both Pierce) and a Syngene
GeneGnome Imaging system. Images were quantified
using GeneQuant software.
Luciferase assays
Luciferase assays were performed in a 6-well plate
format, using a Promega Dual Luciferase Assay Reporter
kit and Turner Instruments 20/20 luminometer, as
described previously [16].
Immunofluorescence and confocal microscopy
Cells were transfected with 500 ng of the relevant plasmid
per coverslip. 24 h post-transfection, cells were treated
with 10 μM MG132 for 1 h to allow accumulation of β-
catenin. Cells were fixed in 4% (w/v) paraformaldehyde
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and stained with antibodies to myc and FLAG (Sigma) as
described previously [14]. Alexa-488 and −546 conjugated
secondary antibodies were from Invitrogen. 4′,6-diami-
dino-2-phenylindole stain (DAPI; Invitrogen) was per-
formed at a 300 nM concentration for 5 min. Confocal
microscopy was performed using a Zeiss LSM 710 META.
All images were taken with a 63× objective. Fluores-
cence exited by the 488, 543 and 633 nm laser lines
of Argon and Helium/Neon lasers was detected separ-
ately using only one laser at the time (multitrack
function) and a combination of band pass filters (BP
505–530, BP 560–615), long pass (LP 560) filters and
meta function (649–798) dependent on the combin-
ation of fluorochromes used.
Statistical analysis
In all cases data are expressed as mean ± SEM, with
values considered statistically significant when p ≤ 0.05.
Student’s t-tests were performed using Microsoft Excel,
other statistical software used is indicated.
Bone analysis
One way analysis of variance (ANOVA) was used to de-
termine the effects of genotype (wild-type and Lrrk2
knockout) on normally distributed trabecular bone data
using GraphPad Prism 6 (GraphPad Software, Inc., San
Diego, CA). For cortical bone, analysis graphs were de-
veloped using the programming language “R”, version
3.1.1 (R Foundation for Statistical Computing, Vienna,
Austria; http://www.r-project.org). Data distribution’s
normality was determined using the Shapiro-Wilk test
and the Kolmogorov-Smirnov goodness of fit test. A sin-
gle factor ANOVA was used to analyse equality of means
between groups. Group means were compared using the
Tukey-Kramer method.
Luciferase assays
Luciferase data in Figs. 2a and 3a, where single pairwise
comparisons were made, were analysed by two-tailed
student’s t-test. All other experiments were analysed by
one-way analysis of variance using SPSS software.
Experiments in Figs. 5d, 6a, b and Additional file 1:
Figure S10, comparing treatments to a single control
(wild-type LRRK2 or DMSO treatment, respectively), were
subjected to post-hoc analysis by two-sided Dunnett’s test-
ing. Bonferroni post-hoc analysis was performed in the
remaining luciferase remaining experiments.
Western blot
Differences between β-catenin expression in wild-type
and LRRK2 knockout mouse brain was assessed by two-
tailed t-testing. Differences between the levels of tran-
scriptionally active ‘free’ β-catenin in wild-type, Lrrk2
heterozygous and Lrrk2 knockout mouse brains was
determined by two-way ANOVA using SPSS software
for the effect of experiment, genotype and the inter-
action between experiment and genotype, followed by
Bonferroni post-hoc testing for the effect of genotype.
Results
Adult Lrrk2 knockout mice exhibit increased predicted
bone strength
Greatly increased bone mineral density has been reported in
the tibiae, femurs and spine of Lrrk1 deficient mice, al-
though the mechanism underlying this osteopetrotic pheno-
type remains unknown [55]. Our previous data
demonstrated that siRNA-mediated knockdown of LRRK1
or LRRK2 elicits increased Wnt signalling in HEK293 cells,
and it is well established that elevated canonical Wnt signal-
ling causes increased bone mass. In light of these observa-
tions we hypothesized that Lrrk2 knockout animals might
also display a bone phenotype consistent with elevated ca-
nonical Wnt signalling. Thus micro-computed tomography
was used to perform a detailed analysis of bone morphology
in tibiae from aged female Lrrk2 knockout mice.
We first studied tibial trabecular bone and found
no differences in tibial length, trabecular tissue vol-
ume (TV), trabecular bone volume (BV), BV/TV, tra-
becular number and thickness (Fig. 1a-b; data not
shown). Cortical bone was next analysed along the
entire tibial length, except for the most proximal and
distal 10%, as these regions include significant tra-
becular content. Statistically significant differences be-
tween the cortical bones of Lrrk2 knockout and wild-
type mice were observed for multiple parameters
(summarized in Fig. 1f ). Consistent with a predicted
increase in bone strength, the second moment of area
around the shortest cross-sectional axis, Imin, was sig-
nificantly greater in knockout animals across almost
the entire cortical length (Fig. 1c). Increased second
moment of area around the longest cross-sectional
axis, Imax, was also observed across most of the bone
length (Fig. 1d). Correspondingly, cross sectional area
(CSA) was also higher (Additional file 2: Figure S1A),
although this only reached statistical significance in a
few regions. We observed a differential effect of Lrrk2
deficiency on the cross sectional thickness (Ct.Th)
parameter, with lower values obtained at a proximal
region, but significantly higher values at two distal re-
gions (Additional file 2: Figure S1B). Lrrk2 deficiency
also elicited a subtle but statistically significant alter-
ation in tibial shape, as evident by changes in ellipti-
city of Lrrk2 knockout tibia in distal regions
(Additional file 2: Figure S1C). Notably, predicted re-
sistance to torsion (J) was significantly increased al-
most across the entire length of Lrrk2 deficient tibiae
(Fig. 1e). Finally, predicted resistance to fracture, as
indicated by section modulus Zmax and Zmin
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(Additional file 3: Figure S2A and B), was also higher
in Lrrk2 deficient mice.
Together these data demonstrate that Lrrk2 deficiency
leads to significant increases in tibial cortical mass and
architecture, and consequently improved predicted
indices of resistance to torsion and fracture in aged
mice. These observations are entirely consistent with
the phenotypic consequence of elevated canonical Wnt
signalling on bone mass and architecture reported pre-
viously [30, 31, 40, 41].
Fig. 1 Lrrk2 knockout mice display increased tibial cortical bone strength. Tibiae from 7 female Lrrk2 knockout (KO) and 7 age and sex-matched wild-
type (WT) mice displayed no differences in a gross morphology or b trabecular bone architecture. However, micro-computed tomographic analysis of
tibial cortical bone revealed c increased second moment of area around the minor axis, Imin; d increased second moment of area around major axis,
Imax; and e increased predicted resistance to torsion, J. f Shows a graphical heatmap displaying statistical differences along the tibia between wild-type
and knockout mice, using 1-way ANOVA followed by Tukey-Kramer post-hoc analysis (blue = n/s, yellow, p < 0.05, green p < 0.01, red, p < 0.001). Note
that in addition to the parameters Imin, Imax and J, other bone parameters were studied, all of which showed differences (see main text for explanation
and Additional file 3: Figure S2 and Additional file 4: Figure S3 for raw data). These altered parameters indicate increased bone strength in Lrrk2
null animals
Berwick et al. Molecular Neurodegeneration  (2017) 12:9 Page 6 of 17
Lrrk2 knockout fibroblasts display enhanced β-catenin
activation
To investigate the effect of LRRK2 loss-of-function on
Wnt signalling more fully, fibroblasts derived from Lrrk2
knockout and wild-type mice [51] were studied using
TOPflash reporter assays [56], which measure β-catenin-
driven transcription to infer levels of transcriptionally
active β-catenin (i.e. levels of canonical Wnt activity). In
agreement with data from siRNA-mediated knockdown
of LRRK2 [16], Lrrk2 knockout cells displayed a small
(~1.8-fold) but significant increase in basal TOPflash
activity compared to wild-type cells (p < 0.001; Fig. 2a).
By contrast, the control FOPflash reporter behaved al-
most identically in both cell types (Fig. 2a). Importantly,
the activity of the Axin2 promoter – a well described ca-
nonical Wnt target – was also elevated in Lrrk2 knock-
out cells (Fig. 3a).
TOPflash assays were next used to investigate the
effect of loss of Lrrk2 on Wnt signalling following treat-
ment with a number of stimuli, namely recombinant
Wnt3a (Fig. 2b), LiCl (Fig. 2c), or co-transfection of
luciferase reporters with plasmids encoding FLAG-β-
catenin (Fig. 2d), FLAG-DVL1 (Additional file 4: Figure
S3A), LRP6-HA and EGFP-FZD5 (Additional file 4:
Figure S3B), or HA-CK1ε (Additional file 4: Figure S3C).
Even correcting for the underlying difference in basal β-
catenin activity, each of these treatments elicited a mark-
edly greater induction of the TOPflash reporter plasmid
in Lrrk2 knockout cells. Differences between values ob-
tained in LRRK2 null cells following pathway activation
and all other TOPflash values were highly significant in
all cases (Fig. 2b-d and Additional file 4: Figure S3A-B,
p < 0.001; Additional file 4: Figure S3C, p < 0.01). Indeed,
in the case of FLAG-β-catenin transfection, the activa-
tion of canonical Wnt activity was over 30 times higher
than in wild-type cells (wild-type ~2.7x, knockout ~87x;
Fig. 2d). By contrast, values from FOPflash were un-
affected by all treatments except co-transfection of
LRP6-HA and EGFP-FZD5 (Additional file 4: Figure
S3B), which mildly repressed the reporter in knockout
cells. This indicates that the true activation of Wnt sig-
nalling by this treatment may be higher than measured
Fig. 2 Lrrk2 knockout cells display increased canonical Wnt activity. a-d Wild-type and Lrrk2 knockout cells were co-transfected with TOPflash or
FOPflash and TK-renilla. a In the absence of canonical Wnt pathway activation, TOPflash activity 24-h post-transfection was significantly higher in
Lrrk2 knockout cells than wild-type controls (n = 36; T-test, p < 0.001). No difference was detected in FOPflash values (n = 30). b Overnight transfection
followed by 6-h treatment with 50 ng/ml recombinant Wnt3a elicited a further increase in TOPflash activity in Lrrk2 knockout cells relative to wild-type
(1-way ANOVA: n = 9; F = 19.143, p < 0.001; Bonferroni post-hoc analysis: p < 0.001 versus all other conditions). No significant changes in FOPflash values
were detected (n = 6, F = 0.40, p = 0.989). c Overnight transfection followed by incubation for 6 h in the presence of 30 mM NaCl or LiCl. 1-way ANOVA
(n = 9; F = 93.414, p < 0.001) followed by Bonferroni post-hoc analysis revealed increased LiCl-driven TOPflash activity in Lrrk2 knockout cells (p < 0.001
relative to all other conditions). No significant changes in FOPflash values were detected (n = 6; F = 2.391, p = 0.1). d Co-transfection with FLAG-β-
catenin or empty vector revealed a marked activation of TOPflash by β-catenin in Lrrk2 knockout cells relative to wild-type cells (n = 9; 1-way ANOVA
(F = 128.490, p < 0.001; Bonferroni post-hoc analysis, p < 0.001 versus all other conditions). No significant changes in FOPflash values were detected
(n = 9, F = 0.165, p = 0.919)
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with TOPflash. In agreement with these data, the Axin2
promoter was also considerably more sensitive to
FLAG-β-catenin overexpression in knockout cells
(Fig. 3b). Thus in agreement with siRNA-mediated
knock-down [16] and the bone phenotype present in
Lrrk2 knockout animals (Fig. 1 , Additional file 2: Figure
S1 and Additional file 3: Figure S2), loss of Lrrk2 in fi-
broblasts leads to an enhancement of both basal and
stimulated canonical Wnt activity.
LRRK2 interacts with and represses β-catenin
The interaction between LRRK2 and β-catenin was next
investigated using confocal microscopy to examine the co-
localisation of FLAG-β-catenin and mycLRRK2 in
HEK293 cells. Owing to the short half-life of β-catenin
[57], cells were treated with the proteosome inhibitor
MG132 for 1 h prior to fixation. As previously reported,
myc-staining revealed the presence of LRRK2 throughout
the cytoplasm, but not in the nucleus (Additional file 5:
Figure S4A). By contrast, FLAG-staining showed β-
catenin to display a prominent nuclear localisation, likely
a consequence of the accumulation of this protein caused
by proteosomal inhibition. Importantly however, β-catenin
was also observed throughout the cytosol, and displayed a
strong co-localisation with LRRK2 in this compartment.
Consistent images could be achieved using antibodies di-
rected to LRRK2 (data not shown) and β-catenin
(Additional file 5: Figure S4B). Interestingly, co-
localisation was most pronounced in punctate structures
that were not readily detectible when either protein was
transfected individually. The nature of these structures is
under investigation, but it is likely they are relevant to
Wnt signalling, since we also found LRRK2 to display
considerable co-localisation with the β-catenin de-
struction complex components AXIN1 (Additional file 6:
Figure S5A) and GSK3β (Additional file 6: Figure S5B). In-
deed, similarly to established β-catenin destruction com-
plex proteins, LRRK2 displayed a striking recruitment into
polymeric AXIN1 structures [58, 59]. These observations
are consistent with our previous finding that Lrrk2 inter-
acts with AXIN1, β-catenin and GSK-3 β endogenously
[16], although we acknowledge that co-localisation data
from over-expressed proteins should always be treated
with caution.
To verify that co-localisation with β-catenin is representa-
tive of physical interaction rather than close spatial proxim-
ity, co-immunoprecipitations were performed. These assays
confirmed that exogenous LRRK2 and β-catenin exist in
complex in HEK293 cells (Additional file 7: Figure S6A).
Importantly, co-immunoprecipitation was performed in the
absence of proteosome inhibition, indicating that the co-
localisation observed by confocal microscopy was not an
artefact of MG132 treatment. Thus, in agreement with co-
immunoprecipitation experiments that were performed in
the reciprocal direction on endogenous protein from mouse
brain extracts [16], LRRK2 and β-catenin appear to interact
strongly in cells.
Since loss of Lrrk2 in vitro had a marked stimulatory
effect on multiple measures of Wnt signalling (Figs. 2, 3,
and Additional file 4: Figure S3), our data suggested
LRRK2 binding to β-catenin protein was exerting an in-
hibitory influence on this Wnt signalling effector. This
idea was investigated further by performing a reciprocal
experiment to that shown in Fig. 2d, examining the ef-
fect of LRRK2 over-expression on β-catenin-driven
TOPflash activity. Consistent with a high turnover of β-
catenin in HEK293 cells, exogenous β-catenin elicited a
small (~2.5x) activation of TOPflash activity (Additional
file 7: Figure S6B). The extent of this activation is similar
to the ~2.7-fold activation observed in wild-type fibro-
blasts (Fig. 2d). In agreement with previous data [16],
over-expression of LRRK2 alone had no significant effect
on this system. However, consistent with the idea that
LRRK2 inhibits β-catenin, co-transfection of LRRK2 with
β-catenin produced a marked reduction in the capacity
of β-catenin to activate the TOPflash reporter
(Additional file 7: Figure S6B).
Increased β-catenin in the Lrrk2 knockout brain
Our data suggested LRRK2 binds and represses the
transcriptional activity of β-catenin, with loss of LRRK2
relieving this repression, thereby causing elevated canon-
ical Wnt signalling. This idea is consistent with the role
for LRRK2 in the β-catenin destruction complex that we
Fig. 3 Lrrk2 knockout cells display increased Axin2 promoter activity.
Wild-type and Lrrk2 MEFs were co-transfected with a reporter plasmid
containing the murine Axin2 promoter upstream of luciferase and TK-
renilla. The relative luciferase activity of resultant cell lysates was
measured 24 h post-transfection. a In the absence of canonical Wnt
pathway activation, Axin2 promoter activity was significantly higher in
Lrrk2 knock-out cells than wild-type controls (n = 18; T-test, p < 0.001). b
Co-transfection with FLAG-β-catenin or empty vector revealed a
marked activation of the Axin2 reporter by β-catenin in Lrrk2 knockout
cells (n = 9; 1-way ANOVA (F = 8.037, p < 0.001) followed by Bonferroni
post-hoc analysis, p < 0.01 versus all other conditions)
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postulated previously [16]. Since the best-described role
for LRRK2 is in Parkinson’s disease, we sought to cor-
roborate this idea in mouse brain.
Western blotting of whole brain lysates from 22 to 26
week old male Lrrk2 null mice revealed a small increase
in total β-catenin levels relative to wild-type controls
(Fig. 4a, b, and Additional file 8: Figure S7). Although
this data is in agreement with LRRK2 repressing β-
catenin, it is well established that free β-catenin – the
transcriptionally active form of β-catenin that is the
output of canonical Wnt signalling – only represents a
fraction of total β-catenin. As such, altered total β-
catenin may be caused by changes in other pools of this
protein. In addition, should canonical Wnt signalling be
altered, the presence of other pools of β-catenin diluting
the transcriptionally active fraction of β-catenin mean
that changes in total β-catenin may not reflect the true
extent of altered Wnt signalling activity. Perhaps in
agreement with this, although basal Wnt signalling is el-
evated in Lrrk2 KO MEFS (Figs. 2a and 3a), we failed to
see reproducible changes in total β-catenin levels in
these cells (data not shown). To address these issues we
adapted the E-cadherin cytosolic tail (ECT) assays devel-
oped by Luckert and colleagues for use in brain extracts
[46]. These assays take advantage of the fact that ECT
binds free β-catenin with high affinity, but is unable to
bind β-catenin in complex with other proteins. As illus-
trated in Fig. 4c, recombinant ECT expressed as a GST
fusion protein and coupled to glutathione-Sepharose
beads can be used as an effective tool to purify free β-
catenin from cell lysates. Importantly, data from ECT as-
says correlate well with parallel TOPflash assays [46].
ECT assays performed on brain extracts from a set of
male Lrrk2 knockout, Lrrk2 heterozygous and wild-type
mice revealed a marked increase in the levels of free β-
catenin with loss of Lrrk2 (Fig. 4d, Additional file 9: Figure
S8A). These data also suggested a gene dosage effect, with
free β-catenin levels higher in knockout than heterozygous
brains. We sought to replicate these observation using ma-
terial from aged female animals consistent with the cohort
used in bone morphology analysis (Fig. 1). The differences
between groups are less than observed in younger male
Fig. 4 Lrrk2 knockout mice display elevated β-catenin levels in the brain. Whole brain lysates from aged-matched Lrrk2 knockout (KO) and wild-type
(WT) male mice were resolved by SDS-PAGE and blotted, as indicated, for Lrrk2, β-catenin and β-actin as a loading control. a Shows representative
images for 3 wild-type and 3 knockout mice. b Mean β-catenin/β-actin ratios for ten wild-type and 11 knockout mice, ± the standard error of the
mean. These calculations revealed significantly increased β-catenin levels in Lrrk2 knockout mouse brains (t-test, p = 0.015). c Graphical illustration of
ECT assays. Immobilised E-cadherin cytosolic tail protein (green) bound to beads can be used to affinity purify free β-catenin (red) from complexed β-
catenin in lysates. d, e ECT assays of lysates from male and female Lrrk2 knockout and heterozygous brains reveal increased free β-catenin in knockout
brains with intermediate levels in heterozygotes. f Analysis of all ECT data by 2-way ANOVA followed by Bonferroni post-hoc testing reveals significant
effects of Lrrk2 deficiency on free β-catenin levels in the brain
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animals, and consistently we were unable to detect differ-
ences in total β-catenin levels (Additional file 9: Figure
S8B). Nonetheless, aged Lrrk2 deficient female brains still
showed increased free β-catenin, with heterozygotes dis-
playing an intermediate level (Fig. 4e, Additional file 9: Fig-
ure S8C). Analysis of the combined data using 2-way
ANOVA confirmed the significant effect of genotype on
free β-catenin (F = 384.945, p < 0.001; Fig. 4f), as well as sig-
nificant effects of experiment and the interaction between
genotype and experiment on this variable. Importantly,
Bonferroni post-hoc testing revealed that the differences
between all three genotypes are highly significant (p < 0.001
for all pairwise comparisons). Thus, in addition to causing
an increase in total β-catenin in the brains of younger male
Lrrk2 knockout mice, loss of Lrrk2 causes a dose-
dependent elevation of free β-catenin in the brains of both
younger males and aged females, albeit to different extents.
Taken together, these data provide strong evidence for ele-
vated canonical Wnt signalling in the brains of Lrrk2 defi-
cient animals.
LRRK2 kinase inhibition weakens basal canonical Wnt
signalling
We previously reported that the LRRK2 kinase inhibitor
LRRK2-in-1 [52] represses TOPflash activity driven by
DVL1 over-expression in SH-SY5Y cells, when applied at
1 μM [16]. However, this compound is known to inhibit
other kinases, suggesting that repression of Wnt signal-
ling may not be specific to LRRK2. This was a major
concern since canonical Wnt signalling is regulated by a
large number of kinases [60]. Thus, the experiment was
repeated over a concentration gradient, to look for ef-
fects at concentrations closer to the reported IC50 for
the compound, and in a second cell line, HEK293 cells.
In addition, two unrelated LRRK2 kinase inhibitors,
TAE684 [53] and CZC25146 [54], both of which have
also been reported to display off-target effects, were
studied in parallel.
In agreement with previous data, 1 μM LRRK2-in-1
produced a robust inhibition of DVL1-driven TOPflash
activity (~12% of DMSO control; Fig. 5a), with a mild
effect apparent at 100nM (~68% of DMSO). This is con-
sistent with the reported in vitro IC50 for this com-
pound of 13 nM [52]. Strong TOPflash inhibition was
also seen with 1 μM TAE684 (~29% of DMSO).
Surprisingly however, CZC25146 had the opposite effect,
inducing a small activation of TOPflash at this concen-
tration (~128% of DMSO). To corroborate this observa-
tion, the CZC25146 concentration gradient was
extended to 5 μM for the final repeat. Under these
Fig. 5 Effect of LRRK2 kinase inhibition on canonical Wnt signalling. a HEK293 cells transfected with TOPflash and FLAG-DVL1 were treated with
DMSO or LRRK2-in-1, TAE684, or CZC-25146 for 20 h at the indicated concentrations. Resultant luciferase values are expressed relative to DMSO
controls. b-d The effect of kinase inhibion with these compounds was further analysed by comparing effects in wild-type and Lrrk2 knockout (KO)
cells. b At concentrations used LRRK2 phosphorylation at serine-935 is reduced. c Using conditions identical to panel A, the three compounds also
display differing effects in wild-type and Lrrk2 knockout cells. d The values produced for each inhibitor in panel C were expressed as a ratio of
wild-type cells over knockout cells, indicating that LRRK2 inhibition weakens DVL1-driven canonical Wnt signalling. 1-way ANOVA reveals a
significant effect of treatment (n = 12, F = 8.628, p < 0.001), with 2-sided Dunnett’s post-hoc analysis indicating significant differences between all
treatments relative to control (LRRK2-in-1, p < 0.05; TAE684, p < 0.05; 1 μM CZC-25146, p < 0.01; 5 μM CZC-25146, p < 0.001)
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conditions it was clear that in contrast to the two other
LRRK2 kinase inhibitors, CZC25146 stimulates the ca-
nonical Wnt pathway.
Although two of the three inhibitors gave data consist-
ent with our previous observation, the contrasting effects
of CZC25146 was a great concern, indicating that off-
target kinase inhibition was affecting our data. We thus
decided to compare the effects of the compounds by per-
forming parallel TOPflash assays in Lrrk2 knockout and
wild-type fibroblasts. Since only wild-type cells express
Lrrk2, values obtained from these cells are the product of
both on- and off-target kinase inhibition, whilst values
from knockout cells can only be the product of off-
targeting. Our objective was to express the values re-
corded in both cell lines as a ratio from which the specific
effect of LRRK2 kinase inhibition can be inferred. Follow-
ing our observations made in Fig. 5a, all three compounds
were applied at 1 μM, with CZC25146 also studied at
5 μM. Under these conditions Lrrk2 kinase activity was ef-
ficiently suppressed, as evidenced by decreased phosphor-
ylation in wild-type cells of Lrrk2 at serine-935, which is
known to be dependent on LRRK2 kinase activity (Fig. 5b
and Additional file 10: Figure S9; [52]).
TOPflash assays performed in wildtype and Lrrk2
knockout cell lines allowed two observations to be made.
Firstly, as evidenced by the inhibitory and stimulatory ef-
fects of TAE264 and CZC25146 respectively in Lrrk2
null cells, both compounds clearly exhibit off-target ef-
fects in these assays (Fig. 5c). Secondly however, com-
parison of the TOPflash values obtained in both cell
lines as a ratio to account for non-specific effects yields
consistent results for all three compounds (Fig. 5d). Re-
markably, at 1 μM the three LRRK2 kinase inhibitors
elicited comparable and statistically significant decreases
in TOPflash activity (2-in-1 ~ 71%, TAE684 ~ 68%, and
CZC25146 ~ 60% relative to DMSO). Treatment with
5 μM CZC25146 yielded an even greater inhibition
(~35% of DMSO). In conclusion therefore, pharmaco-
logical inhibitors of LRRK2 produce disparate effects on
DVL1-driven canonical Wnt signalling that are at least in
part caused by non-specific kinase inhibition. As such,
these data must be treated with caution. However, our
data suggest strongly that the inhibition of LRRK2 kinase
activity per se represses activity of this signalling cascade.
We have previously reported that LRRK2 mutants con-
taining kinase-dead and GTP-non-binding amino-acid
substitutions reduced the capacity of over-expressed
LRRK2 to enhance Dvl1-driven Wnt signalling [16]. These
assays have produced consistent data, but are clearly not
reflective of physiological Wnt signalling. To address this
issue we chose to investigate the effect of over-expressing
LRRK2 mutants on TOPflash activity under tonic condi-
tions. Such assays have proven troublesome in other cell
types due to the poor signal-to-noise ratios achieved in
the absence of pathway stimulation (data not shown).
However, since Lrrk2 knockout fibroblasts have elevated
basal TOPflash activity, we hypothesized that these cells
might be a suitable model for these experiments. Further-
more, assaying the effects of LRRK2 mutations in knock-
out cells has the additional advantage of removing
competition from endogenous Lrrk2 protein.
The effect of artificial kinase-dead mutations in LRRK2
was thus tested in Lrrk2 knockout cells. In agreement
with data from DVL1-driven TOPlash assays, kinase in-
activation was found to inhibit basal Wnt activity by at
least 50% relative to wild-type LRRK2 (Additional file 1:
Figure S10). Two further artificial LRRK2 mutants were
assayed: K1347A and T1348N. Both of these variants ab-
rogate the binding of the LRRK2 RocCOR domain to
guanyl nucleotides. We have previously reported that
K1347A inhibits the effect of LRRK2 over-expression on
DVL1-driven TOPflash activity similarly to kinase-dead
mutations [16]. To our surprise, neither K1347A nor
T1348N produced any statistically significant effects on
basal TOPflash activity (Additional file 1: Figure S10).
PD-causing LRRK2 mutations weaken basal Wnt signalling
Finally, we sought to use Lrrk2 knockout fibroblasts to
determine the effect of pathogenic LRRK2 mutations on
basal canonical Wnt signalling. We firstly tested
R1441C, Y1699C and G2019S, which we have previously
reported to weaken the effect of LRRK2 over-expression
on DVL1-driven TOPflash activity [16]. The pathogenic
R1441G mutant was assayed in parallel. Remarkably, all
four PD-causing mutations weakened basal canonical
Wnt signalling (Fig. 6a), although the effect of R1441C
did not reach statistical significance. In light of this re-
sult, three further PD-associated variants, N1437H,
R1628P and G2385R, were examined in this assay,
alongside a LRRK2 construct containing the protective
R1398H mutation. Each of these pathogenic variants
qualitatively weakened Wnt signalling, although only the
effect of G2385R reached significance (Fig. 6b). Remark-
ably however, R1398H produced the opposite result: a
statistically significant increase in TOPflash activity. Im-
portantly, the data from the G2385R and R1398H mu-
tants corroborate results from our DVL1-driven
TOPflash model [18]. Taken together, these data provide
strong evidence that PD-causing mutations throughout
LRRK2 weaken the activity of the canonical Wnt path-
way under tonic conditions. In stark contrast, the PD-
protective R1398H variant increases the strength of this
pathway.
Discussion
Herein, we present evidence that loss of LRRK2 leads to
elevated canonical Wnt signalling in vivo. We report for
the first time that Lrrk2 knockout mice exhibit elevated
Berwick et al. Molecular Neurodegeneration  (2017) 12:9 Page 11 of 17
levels of transcriptionally active free β-catenin in the
brain (Fig. 4), and show a corresponding increase in pre-
dicted bone strength in aged mice (Fig. 1). Accordingly,
Lrrk2 knockout fibroblasts display elevated canonical
Wnt activity – both basally and following pathway
stimulation (Fig. 2) – as well as increased activity of the
Axin2 promoter, a canonical Wnt target (Fig. 3). Provid-
ing a mechanistic rationale for these observations,
LRRK2 binds β-catenin and represses the transcriptional
activity of this protein (Additional file 5: Figure S4,
Additional file 6: Figure S5 and Additional file 7:
Figure S6). Taken together, these data are consistent
with a role for LRRK2 as a component of the β-
catenin destruction complex. Using fibroblasts derived
from knockout mice, we also performed a thorough
characterisation of the effects of LRRK2 kinase inhib-
ition on canonical Wnt signalling, finding strong evi-
dence that such compounds suppress the pathway
(Fig. 5). Finally, we show that under basal conditions,
PD causing LRRK2 mutations repress canonical Wnt
activity, whilst the protective R1398H mutation has
the opposite effect (Fig. 6). These last observations
suggest that in the context of canonical Wnt signal-
ling, pathological LRRK2 mutations are gain-of-
function, enhancing the repression of β-catenin medi-
ated by LRRK2.
Our data add to the growing body of work implicating
deregulated canonical Wnt activity in neurodegeneration
in general and Parkinson’s disease in particular. In
addition to LRRK2, a remarkable number of genes linked
to PD have been shown to modulate the canonical Wnt
pathway, for example VPS35, PINK1, UCHL-1, Parkin,
ATP6AP2, and GBA [61–66]. Furthermore, the integral
Wnt component GSK3β has been implicated in the
modulation of PD risk [67]. Supporting this idea, the
differentiation of the dopaminergic neurones of the
substantia nigra that are lost in PD appears to be exquis-
itely sensitive to Wnt signalling [68, 69]. Furthermore,
Wnt signalling is vital for adult neurogenesis [70] and
for the normal function of mature neurones [71, 72].
Since the neuroprotective capacity of canonical Wnt sig-
nalling is also well described [27, 71, 73] and altered
Wnt signalling has already been reported in the brains
of PD patients and model animals [74–76], modifying
Wnt activity is evidently a plausible therapeutic strategy
for PD.
In this report we provide the first evidence that Lrrk2
deficiency alters bone mass and architecture, which is
consistent with a mild elevation in canonical Wnt signal-
ling. It is very difficult to speculate which mechanisms
and cell types are involved, since the canonical Wnt sig-
nalling pathway regulates bone mass through a number
of different mechanisms. These include renewal of stem
cells [77], stimulation of osteoblast differentiation and
proliferation [40], enhancement of osteoblast activity
[31, 40], inhibition of osteoblast and osteocyte apoptosis
[30], regulation of osteoclastogenesis [36, 39] and
modulation of adaptive responses to mechanical strain
[41, 78–82]. This last phenomenon is particularly intri-
guing in the context of a gene involved in Parkinson’s
disease, since it creates a mechanism whereby altered
bone strength may be manifest with ageing.
We note that our study is not the first to assess bone
microarchitecture in Lrrk2 deficient animals, and at first
glance the two reports appear in conflict. Specifically,
Xing and colleagues found bones from Lrrk2 knockout
mice to be no different to wild-type – albeit with the im-
portant caveat that 8-week old males were used, whereas
we used 60–64 week old females [55]. The authors, how-
ever, reported that targeted disruption of Lrrk1 leads to
severe osteopetrosis. This age and sex difference is
clearly sufficient to account for any discord. However,
Fig. 6 Effect of LRRK2 mutations on basal Wnt signalling. Lrrk2 knockout (KO) cells were transfected with TOPflash or FOPflash plus wild-type
LRRK2 or the indicated LRRK2 mutant. a 1-way ANOVA (n = 9-15, F = 3.296, p < 0.05) followed by 2-sided Dunnett’s post-hoc analysis indicate that
pathogenic LRRK2 mutations weaken canonical Wnt signalling relative to wild-type LRRK2 (RG, p < 0.05; YC, p < 0.05; GS, p < 0.05). RC is decreased
relative to wild-type but does not reach significance. b 1-way ANOVA (n = 9, F = 13.388, p < 0.001) followed by 2-sided Dunnett’s post-hoc analysis
indicate the pathogenic LRRK2 mutation GR weakens basal canonical Wnt signalling relative to wild-type LRRK2 (p < 0.01), whilst the protective RH
mutation enhances canonical Wnt activity (p < 0.01). Note that the pathogenic mutations NH and RP decreased relative to wild-type but neither
reaches significance. Mutations used: RC = R1441C, RG = R1441G, YC = Y1699C, GS = G2019S, NH= N1437H, RP = R1628P, GR = G2385R; RH = R1398H
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closer inspection indicates that the two studies are in fact in
agreement, since Xing and colleagues only examined tra-
becular bone [55]. We also found no phenotype in this bone
type (Fig. 1a, b), with evidence of increased bone strength
only present in cortical bone. Evidently, future studies will
need to compare the bone parameters of Lrrk1 and Lrrk2
null mice directly, using both cortical and trabecular bone,
and in males and females over a range of ages.
It would also be informative to study Lrrk1/Lrrk2 double
knockout animals in parallel, but what bone phenotype
might one expect? Intuitively one would assume a more se-
vere phenotype, which is supported by previous studies of
canonical Wnt pathway components using double knock-
out animals. For example, the following double knockout
mice – Lef/Tcf1, Lrp5/Lrp6, Wnt1/Wnt3a, Dvl1/Dvl2,
Krm1/Krm2 – all display more pronounced developmental
defects than corresponding single knockouts [83–89]. In-
deed, Krm1/Krm2 mice show increased bone density, even
though Krm1 and Krm2 null animals have normal bone pa-
rameters [89]. Such predictions must of course be made
with caution, especially since we do not know the mecha-
nisms by which Lrrk1 and Lrrk2 affect bone. Nonetheless
we believe there is sufficient evidence to expect a more se-
vere phenotype in Lrrk1/Lrrk2 animals than seen in either
single knockout.
The relative subtlety of the Lrrk2 bone phenotype not-
withstanding, our data raise the question as to why ana-
tomical phenotypes associated with elevated canonical
Wnt signalling have not been reported previously. In the
case of the most studied organ, the brain, decreased ca-
nonical Wnt activity produces well described develop-
mental defects [68, 69], but increased Wnt is not
associated with an obvious phenotype. It is therefore un-
surprising that Lrrk2 knockout brains display no appar-
ent defects. Nonetheless, Wnt signalling is well known
to promote neurite outgrowth and a number of studies
have observed increased neurite length in neurones
explanted from Lrrk2 null animals (reviewed in [90]).
Thus, loss of Lrrk2 may produce subtle developmental
differences that are presumably transient and recover-
able. In contrast to brain, Lrrk2 knockout animals do
have a widely reported kidney phenotype, as well as
defects in liver and lung [91–93]. Intriguingly, elevated
canonical Wnt signalling is associated with a remarkable
range of kidney diseases, including acute kidney injury,
diabetic nephropathy, tubulointerstitial fibrosis and poly-
cystic kidney disease [24], and also causes fibrotic condi-
tions in certain other organs, including both liver and
lung [94]. As such, the possibility that increased canon-
ical Wnt activation underlies these phenotypes requires
investigation, for example by crossing Lrrk2 deficient
mice with animals with decreased Wnt signalling.
Finally, increased predicted bone strength in Lrrk2 null
mice is particularly interesting to consider in light of the
growing links between Parkinson’s disease and osteoporosis.
It has long been known that PD patients are at increased
risk of bone fractures, although this has traditionally been
accounted for by the greater risk of falling due to postural
instability, together with less exercise creating more fragile
bones directly and indirectly via less exposure to sunlight
(leading to lower Vitamin D). However, recent advances
suggest osteoporosis and PD are more intimately linked,
with rates of co-morbidity far higher than assumed [95]. In
fact, Invernizzi and colleagues reported osteoporosis or
osteopenia (in which bone density is decreased to a lesser
extent than osteoporosis) in as much as 91% of female PD
patients and 61% of males [96]. A recent meta-analysis esti-
mated this “osteoporosis or osteopenia in PD” odds ratio as
2.61 compared to healthy controls [97]. As such, it is tempt-
ing to speculate that osteoporosis and PD may share some
common etiology. We have yet to examine bone parameters
in transgenic mice with pathological Lrrk2 mutations, and
we are unaware of any similar studies on human LRRK2 pa-
tients or unaffected carriers. However, our data suggest
strongly that these individuals have lowered canonical Wnt
activity (Fig. 5; [16, 18]), which in turn would predict de-
creased bone strength. It would clearly be interesting not
only to investigate this hypothesis, but to determine whether
altered bone parameters can occur in the absence of (or be-
fore) motor symptoms. Given that so many other PD-
causing mutations have been reported to repress Wnt sig-
nalling [61–63, 65, 66], the links between PD and bone
health warrant further investigation. Furthermore, since half
of all bone fractures in PD are hip fractures and these injur-
ies carry a bleak 1-year mortality rate of 30% [97], pharma-
cological treatments that improve neuronal survival and
increase bone strength would be particularly welcome.
Conclusions
Our data indicate that LRRK2 is a repressor of β-catenin
and therefore Lrrk2 deficient mice display elevated
canonical Wnt signalling and increased indices of pre-
dicted bone strength. Four out of seven pathogenic
LRRK2 mutations are associated with statistically signifi-
cant increases in repression of Wnt activity, whilst a
protective mutation has the opposite effect. Thus, this
study supports the connection between decreased Wnt
signalling and Parkinson’s disease, and suggests that the
deregulation of this pathway may not only contribute to
neurodegeneration, but may also account for the in-
creased incidence of osteoporosis seen in PD patients.
Additional files
Additional file 1: Figure S10. Kinase-dead but not GTP-non-binding
mutations weaken basal Wnt signalling. Lrrk2 knockout (KO) cells were
transfected with TOPflash or FOPflash plus wild-type LRRK2 or the indi-
cated LRRK2 mutant. 1-way ANOVA (n = 12–15, F = 7.449, p < 0.001)
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followed by 2-sided Dunnett’s post-hoc analysis indicate that kinase-dead
mutations significantly weaken canonical Wnt signalling relative to wild-
type LRRK2 (1994, p < 0.05; 2017, p < 0.05). Mutations used: kinase-dead:
1994 = D1994A, 2017 = D2017A; guanyl nucleotide-non-binding: KA =
K1347A, TN = T1348N. (PDF 46 kb)
Additional file 2: Figure S1. Effects of loss of Lrrk2 on tibial cortical
Cross Sectional Area, Mean Cortical Thickness, and Ellipticity. Images in
Figures A, B and C show i) values for cross-sectional area, mean cortical
thickness and ellipticity, respectively in female wild-type (WT) and Lrrk2
knockout (KO) mice; together with ii) the same data expressed as a
graphical heat map along the tibial length; and iii) the points at which
differences between genotypes for these parameters become statistically
significant. (blue = n/s, yellow, p < 0.05, green p < 0.01, red, p < 0.001).
(PDF 131 kb)
Additional file 3: Figure S2. Effects of loss of Lrrk2 on tibial cortical
Zmax and Zmin. Images in Figures A and B show i) values for Zmax and
Zmin, predicted resistance to fracture along the shortest and longest
cross-sectional axes, respectively in female wild-type (WT) and Lrrk2
knockout (KO) mice; together with ii) the same data expressed as a
graphical heat map along the tibial length; and iii) the points at which
differences between genotypes for these parameters become statistically
significant. (blue = n/s, yellow, p < 0.05, green p < 0.01, red, p < 0.001).
(PDF 110 kb)
Additional file 4: Figure S3. Increased canonical Wnt activity in Lrrk2
knockout cells. A, B) Cells were transfected with TK-renilla and TOPflash or
FOPflash in the presence of A) FLAG-DVl1 or C) GFP-FZD5 and HA-LRP6,
or appropriate vector controls. A) 1-way ANOVA (n = 9; F = 146.199, p <
0.001) followed by Bonferroni post-hoc analysis revealed increased DVL1-
driven TOPflash activity in Lrrk2 knockout cells (p < 0.001 versus all other
conditions). No significant changes in FOPflash values were detected
(n = 9; F = 2.668, p = 0.064). B) 1-way ANOVA (n = 9; F = 70.694, p < 0.001)
followed by Bonferroni post-hoc analysis revealed increased GFP-FZD5/
HA-LRP6-driven TOPflash activity in Lrrk2 knockout cells (p < 0.001 versus
all other conditions). By contrast, the same treatment elicited a significant
decrease in FOPflash values (1-way ANOVA: n = 6; F = 11.129, p = 0.001.
Bonferroni post-hoc analysis p < 0.001). C) Wild-type and Lrrk2 MEFs were
co-transfected with TK-renilla and TOPflash or FOPflash in the presence of
active or inactive (KR) HA-tagged CK1ε. 1-way ANOVA (n = 9; F = 7.619, p
= 0.001) followed by Bonferroni post-hoc analysis revealed increased
CK1ε-driven TOPflash activity in Lrrk2 knockout cells (p < 0.01 versus all
other conditions). No significant changes in FOPflash values were
detected (n = 3; F = 1.535, p = 0.279). (PDF 90 kb)
Additional file 5: Figure S4. Association of mycLRRK2 and FLAG-β-catenin
in HEK293 cells 24 h post transfection, cells expressing myc-tagged LRRK2 and
FLAG-tagged β-catenin were treated with MG132 for 1 h to allow β-catenin ac-
cumulation. The cells were subsequently fixed and stained with antibodies for
A) myc (green) and FLAG (red), or B) myc (green) and β-catenin (red). DAPI
staining (blue) was also performed to show cell nuclei. The right-hand panel
shows an overlay of all channels – note the considerable co-localisation
between LRRK2 and β-catenin in the cytoplasm. (PDF 102 kb)
Additional file 6: Figure S5. Co-localisation between mycLRRK2 and
HA-AXIN1, and mycLRRK2 and HA-GSK3β in HEK293 cells. A) Recruitment
of mycLRRK2 (green) into polymers formed by HA-AXIN1 (red). Magnified
images of a selected region are included. B) shows cytoplasmic co-
localisation between mycLRRK2 (green) and HA-GSK3β (red), also with
magnified images included. Note that in both experiments, counterstaining
with phalloidin (blue) and DAPI (grey) were performed to visualise
filamentous actin and chromosomal DNA respectively. The scale bar =
10 μm. (PDF 92 kb)
Additional file 7: Figure S6. LRRK2 interacts with β-catenin and represses
β-catenin-driven TOPflash activity. A) HEK293 cells were co-transfected with
FLAG-tagged β-catenin (lanes 1 and 4), myc-tagged LRRK2 (lanes 2 and 5), or
myc-tagged LRRK2 and FLAG-tagged β-catenin (lanes 3 and 6) for 24 h prior to
lysis. Lysates were immunoprecipitated with anti-FLAG antibodies and bound
protein was resolved by Western blot (lanes 4–6), with the original lysates run
alongside to confirm expression of transfected protein (lanes 1–3). Myc-tagged
LRRK2 can clearly be seen in anti-FLAG immunoprecipitates from co-transfected
cells (lane 6, upper panel). Full images of all blots are also shown. B) HEK293
cells were transfected with the TOPflash or FOPflash reporter plasmids with the
indicated combinations of mycLRRK2, FLAG-β-catenin or appropriate control
vectors. After 24 h lysates were taken and luciferase activity measured. 1-way
ANOVA of TOPflash values revealed a significant effect of transfection on
canonical Wnt activity (n= 9, F = 44.893, p< 0.001). Post-hoc Bonferroni testing
showed significantly increased Wnt signalling caused by FLAG-β-catenin
transfection in the presence or absence of mycLRRK2 co-transfection (p< 0.001
in both cases). Importantly however, co-transfected mycLRRK2 significantly
weakened the TOPflash activation elicited by FLAG-β-catenin (p< 0.001).
ANOVA of control FOPflash values also revealed significant effects of treatment,
however Bonferroni post-hoc analysis found no significant differences in any
pair-wise comparison. (PDF 129 kb)
Additional file 8: Figure S7. Entire images of Western Blots shown in
Fig. 4a. (PDF 70 kb)
Additional file 9: Figure S8. Entire images of Western Blots shown in
Fig. 4D and E and total β-catenin levels in aged female mouse brains A)
Full blot from the image shown in Fig. 4d, plus a reprobe of the same
membrane for calnexin to show that pulldowns are clean and this
protein is only present in cell lysates. B) Western blotting shows no
discernible differences between levels of total β-catenin in brains from
aged female mice. C) Full blot from the image shown in Fig. 4e. (PDF 102 kb)
Additional file 10: Figure S9. Entire images of Western Blots shown in
Fig. 5b. (PDF 80 kb)
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